Alexandria Real Estate Equities, Inc. issued a press release on October 29, 2026, announcing its participation in the 20th anniversary Prix Galien USA Forum in New York City and its role as founding strategic partner of the MAP-D depression research initiative.

Key Highlights

  • MAP-D design phase complete: According to the filing, the MAP-D initiative completed its critical design phase in June 2026 and began advancing toward a first-of-its-kind longitudinal clinical study.
  • Three-year pilot planned: The filing states the pilot will use advanced artificial intelligence models to identify relationships between biological markers and patient outcomes.
  • Nilo Therapeutics Series A: The filing discloses that Alexandria Venture Investments participated in an oversubscribed $101 million Series A financing of NYC-based Nilo Therapeutics in October 2025, alongside the Gates Foundation.
  • Eikon Therapeutics IPO: The filing states that Eikon Therapeutics completed an upsized $381 million initial public offering in February 2026.
  • ITCI acquisition: The filing references the $14.6 billion acquisition of Intra-Cellular Therapies, Inc. by Johnson and Johnson in 2025 as an outcome of an AVI investment dating to 2002.
  • Panel co-moderation: Joel S. Marcus, executive chairman and founder, and Lynne Zydowsky, PhD, chief of science, will co-moderate the MAP-D panel discussion at the Galien Forum USA, according to the filing.

Alexandria's Role in MAP-D Initiative and NYC Life Science Ecosystem

According to the filing, Alexandria Real Estate Equities (NYSE:ARE) served as the founding strategic partner of the MAP-D initiative, providing the first funding and helping secure cross-sector support required to launch the public-private partnership with the Foundation for the National Institutes of Health (FNIH). The filing states that the initiative, which completed its critical design phase in June 2026, aims to generate "one of the most comprehensive depression research datasets ever assembled" through a longitudinal clinical study integrating biological, clinical, neuroimaging, digital and patient-reported data. The three-year pilot will use advanced artificial intelligence models, and the initiative ultimately aims to establish a scalable precision medicine framework for depression, with stated potential to extend its impact to other serious mental illnesses.

The filing also highlights Alexandria Venture Investments' (AVI) activity in New York City, describing it as "the second most active institutional life science investor in NYC." The filing traces AVI's NYC venture history to a 2002 Series A participation in Intra-Cellular Therapies, Inc. (ITCI), which the filing states was later acquired by Johnson and Johnson in 2025 for $14.6 billion. Joel S. Marcus is noted in the filing as having served on ITCI's board of directors from 2006 through its acquisition. More recently, the filing discloses AVI's participation in Nilo Therapeutics' $101 million Series A in October 2025 and notes that Eikon Therapeutics, described as an AVI portfolio company with East Coast operations at the Alexandria Center for Life Science in NYC, completed an upsized $381 million IPO in February 2026.

The filing includes forward-looking statements regarding the MAP-D initiative's anticipated timing, scope, and potential outcomes, and notes these are "not guaranteed to occur." The filing states that Alexandria assumes no obligation to update or revise any forward-looking statement except as required by law, and directs readers to its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q for a fuller discussion of risks and uncertainties.

What Was Disclosed

Alexandria Real Estate Equities disclosed its founding partnership role in the MAP-D depression research initiative, recent AVI venture activity in New York City including the Nilo Therapeutics and Eikon Therapeutics financings, and its participation in the 20th Prix Galien USA Forum on October 29, 2026.